Please assess the completion status of the following clinical trial:

Trial Title: Adult Patients Undergoing Open Colectomy MA402S23B303

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and older.~* Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.~* Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study.~* Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in an EXPAREL study within the last 30 days.~* Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~* Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery~In addition, the patient will be ineligible if he/she meets the following criteria during surgery:~* Patients who have any concurrent surgical procedure.~* Patients with unplanned multiple segmental resections or large intestine.~* Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV morphine sulfate (Type: ACTIVE_COMPARATOR): Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
- EXPAREL (bupivacaine liposome injectable suspension) (Type: EXPERIMENTAL): EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.

Based on this trial design, predict the completion outcome and termination type (if applicable).